First, as a new oral hypoglycemic drug, DPP4 inhibitors might promote bone formation and inhibit bone absorption in addition to possessing practical hypoglycemic effects, reducing the risk of osteoporosis and fracture (5–9). Here, DPP4 is linked to osteoporosis.